Source: Current Phamaceutical Design. Unidade: FMRP
Subjects: CANNABIS, ANTIPSICÓTICOS, TRANSTORNOS PSICÓTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ZUARDI, Antonio Waldo et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Phamaceutical Design, v. 18, n. 32, p. 5131-5140, 2012Tradução . . Disponível em: https://doi.org/10.2174/138161212802884681. Acesso em: 03 nov. 2024.APA
Zuardi, A. W., Crippa, J. A. de S., Hallak, J. E. C., Bhattacharyya, S., Atakan, Z., Martín-Santos, R., et al. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Phamaceutical Design, 18( 32), 5131-5140. doi:10.2174/138161212802884681NLM
Zuardi AW, Crippa JA de S, Hallak JEC, Bhattacharyya S, Atakan Z, Martín-Santos R, McGuire PK, Guimarães FS. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Internet]. Current Phamaceutical Design. 2012 ; 18( 32): 5131-5140.[citado 2024 nov. 03 ] Available from: https://doi.org/10.2174/138161212802884681Vancouver
Zuardi AW, Crippa JA de S, Hallak JEC, Bhattacharyya S, Atakan Z, Martín-Santos R, McGuire PK, Guimarães FS. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Internet]. Current Phamaceutical Design. 2012 ; 18( 32): 5131-5140.[citado 2024 nov. 03 ] Available from: https://doi.org/10.2174/138161212802884681
